| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Saraswati Sukumar | |
| Pang-Kuo Lo | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation | Q22003769 | ||
| NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas | Q22008613 | ||
| DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development | Q22010765 | ||
| Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? | Q22251049 | ||
| DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci | Q22254582 | ||
| HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells | Q24291505 | ||
| Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation | Q24293278 | ||
| Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family | Q24294179 | ||
| Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing | Q24294291 | ||
| HDAC6 is a microtubule-associated deacetylase | Q24298013 | ||
| Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression | Q24300386 | ||
| Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF | Q24305335 | ||
| Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer | Q24309649 | ||
| MethyLight: a high-throughput assay to measure DNA methylation | Q24515378 | ||
| Comprehensive analysis of CpG islands in human chromosomes 21 and 22 | Q24531622 | ||
| Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription | Q24534441 | ||
| The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a | Q24544000 | ||
| A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands | Q24562877 | ||
| Telomere shortening and apoptosis in telomerase-inhibited human tumor cells | Q24598974 | ||
| Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3 | Q24599788 | ||
| The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes | Q24602177 | ||
| Structure of human DNMT2, an enigmatic DNA methyltransferase homolog that displays denaturant-resistant binding to DNA | Q24621648 | ||
| Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands | Q24631957 | ||
| Genome-wide maps of chromatin state in pluripotent and lineage-committed cells | Q24632506 | ||
| Histone sumoylation is associated with transcriptional repression | Q24656259 | ||
| EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells | Q24672969 | ||
| The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase | Q24678267 | ||
| Comparative isoschizomer profiling of cytosine methylation: the HELP assay | Q24685607 | ||
| SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins | Q24685694 | ||
| Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains | Q27641772 | ||
| Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. | Q53666037 | ||
| Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. | Q54790226 | ||
| Moving AHEAD with an international human epigenome project. | Q55050360 | ||
| The fundamental role of epigenetic events in cancer | Q56421597 | ||
| Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a | Q57277034 | ||
| Circulating Methylated DNA: A New Generation of Tumor Markers | Q61925524 | ||
| Chromosomal Instability and Tumors Promoted by DNA Hypomethylation | Q63253103 | ||
| Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells | Q72386166 | ||
| NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers | Q72992695 | ||
| Epigenetic silencing of maspin gene expression in human breast cancers | Q73527270 | ||
| Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation | Q73715187 | ||
| Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR | Q73852496 | ||
| Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas | Q73963453 | ||
| Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer | Q74088944 | ||
| DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements | Q74578917 | ||
| Hypomethylation of pericentromeric DNA in breast adenocarcinomas | Q77132854 | ||
| Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors | Q77556929 | ||
| Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression | Q77916758 | ||
| Methylation profiling of CpG islands in human breast cancer cells | Q78015848 | ||
| Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival | Q78632811 | ||
| DNA methylation in serum of breast cancer patients: an independent prognostic marker | Q79317164 | ||
| HDAC inhibitors overcome first hurdle | Q79520691 | ||
| Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers | Q79768604 | ||
| Epigenetics and cancer | Q80824706 | ||
| DNA methylation analysis by pyrosequencing | Q81247006 | ||
| Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells | Q34124417 | ||
| Acetylation of beta-catenin by CREB-binding protein (CBP). | Q34125251 | ||
| A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer | Q34126908 | ||
| The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells | Q34144912 | ||
| Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. | Q34225624 | ||
| Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome | Q34231008 | ||
| Stem cells and cancer; the polycomb connection | Q34341685 | ||
| A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases | Q34343364 | ||
| Stat3 dimerization regulated by reversible acetylation of a single lysine residue | Q34384817 | ||
| Co-evolution of X-chromosome inactivation and imprinting in mammals | Q34409829 | ||
| Evidence for an instructive mechanism of de novo methylation in cancer cells. | Q34489258 | ||
| COBRA: a sensitive and quantitative DNA methylation assay | Q34630070 | ||
| The many faces of histone lysine methylation | Q34688382 | ||
| DNA hypomethylation leads to elevated mutation rates | Q34752442 | ||
| DNA methylation and breast carcinogenesis. | Q34770599 | ||
| Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer | Q34774614 | ||
| Genome-wide promoter analysis uncovers portions of the cancer methylome. | Q35008027 | ||
| Diagnosis and Management of Central Nervous System Metastases from Breast Cancer | Q35552601 | ||
| Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. | Q35563726 | ||
| Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer | Q35605804 | ||
| High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer | Q35759154 | ||
| The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. | Q35804605 | ||
| Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis | Q35959363 | ||
| Sin3: a flexible regulator of global gene expression and genome stability. | Q35964130 | ||
| Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects | Q35973630 | ||
| Breast cancer: origins and evolution | Q36099434 | ||
| Prospects: histone deacetylase inhibitors | Q36223192 | ||
| Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid | Q36303956 | ||
| Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk | Q36343107 | ||
| DNA methyltransferases: facts, clues, mysteries. | Q36434817 | ||
| DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines | Q36465214 | ||
| Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences | Q36475874 | ||
| Dual targeting of epigenetic therapy in cancer | Q36576206 | ||
| Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins | Q27860456 | ||
| Worms gang up on bacteria | Q27860588 | ||
| High-resolution profiling of histone methylations in the human genome | Q27860906 | ||
| The genomic landscapes of human breast and colorectal cancers | Q27861078 | ||
| Chd1 chromodomain links histone H3 methylation with SAGA- and SLIK-dependent acetylation | Q27937996 | ||
| Histone demethylation by a family of JmjC domain-containing proteins | Q27939224 | ||
| Role of histone H3 lysine 27 methylation in Polycomb-group silencing | Q28131795 | ||
| Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.3, related to the cytosine-5-methyltransferase 3 gene family | Q28138517 | ||
| Deacetylation of p53 modulates its effect on cell growth and apoptosis | Q28138967 | ||
| TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers | Q28139273 | ||
| DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters | Q28140428 | ||
| Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation | Q28143634 | ||
| Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin | Q28187783 | ||
| CoREST is an integral component of the CoREST- human histone deacetylase complex | Q28199886 | ||
| DNA methylation: a profile of methods and applications | Q28202469 | ||
| DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation | Q28206029 | ||
| Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily | Q28207095 | ||
| N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso | Q28207325 | ||
| Bromodomain: an acetyl-lysine binding domain | Q28209708 | ||
| A gene hypermethylation profile of human cancer | Q28213253 | ||
| Duration of nuclear NF-kappaB action regulated by reversible acetylation | Q28215080 | ||
| Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer | Q28239595 | ||
| Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer | Q28253941 | ||
| Use of restriction enzymes to study eukaryotic DNA methylation: I. The methylation pattern in ribosomal DNA from Xenopus laevis | Q28263661 | ||
| Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer | Q28269763 | ||
| Regulation of LSD1 histone demethylase activity by its associated factors | Q28270391 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| The cancer epigenome--components and functional correlates | Q28278109 | ||
| Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly | Q28278522 | ||
| The epigenomics of cancer | Q28289975 | ||
| Genome regulation by polycomb and trithorax proteins | Q28289984 | ||
| Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer | Q28291617 | ||
| Molecular definition of breast tumor heterogeneity | Q28292256 | ||
| Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis | Q28294866 | ||
| High-resolution genome-wide mapping of histone modifications | Q47244312 | ||
| Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer | Q47255065 | ||
| Mapping of ER gene CpG island methylation-specific polymerase chain reaction. | Q47945083 | ||
| Regulation and function of DNA methylation in vertebrates | Q48034319 | ||
| Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers | Q48277606 | ||
| Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs | Q48289947 | ||
| Imprinting and the epigenetic asymmetry between parental genomes | Q48881402 | ||
| DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. | Q50320380 | ||
| Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. | Q52564601 | ||
| Two-color quantitative multiplex methylation-specific PCR. | Q53348571 | ||
| Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. | Q53429823 | ||
| Methylation-specific digital karyotyping | Q28296362 | ||
| Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers | Q28343483 | ||
| Histone H3 lysine 4 methylation is mediated by Set1 and required for cell growth and rDNA silencing in Saccharomyces cerevisiae | Q28343956 | ||
| Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1 | Q28575665 | ||
| Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9 | Q28594945 | ||
| Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains | Q28609779 | ||
| Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3 | Q28609869 | ||
| MicroRNA biogenesis: coordinated cropping and dicing | Q29547496 | ||
| Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription | Q29547568 | ||
| Genomic maps and comparative analysis of histone modifications in human and mouse | Q29614418 | ||
| The diverse functions of histone lysine methylation | Q29614523 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| Cancer epigenomics: DNA methylomes and histone-modification maps | Q29615524 | ||
| Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer | Q29615649 | ||
| Anticancer activities of histone deacetylase inhibitors | Q29616624 | ||
| Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome | Q29616819 | ||
| The history of cancer epigenetics | Q29617273 | ||
| Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome | Q29618064 | ||
| Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells | Q29618090 | ||
| Hypomethylation distinguishes genes of some human cancers from their normal counterparts | Q29619217 | ||
| Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression | Q29619380 | ||
| Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer | Q29622925 | ||
| Effector proteins for methylated histones: an expanding family | Q30437185 | ||
| CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer | Q33235269 | ||
| A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer | Q33267359 | ||
| Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes | Q33335165 | ||
| Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin? | Q33864653 | ||
| Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. | Q33888431 | ||
| Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors | Q33935153 | ||
| Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation | Q33988438 | ||
| Chasing the cancer demon | Q34090719 | ||
| Histone deacetylase inhibitors: signalling towards p21cip1/waf1. | Q36782509 | ||
| Cell type-specific DNA methylation patterns in the human breast | Q36869180 | ||
| Retinoids in biological control and cancer | Q36954461 | ||
| Histone deacetylase inhibitors for cancer therapy. | Q36999619 | ||
| Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis | Q38341003 | ||
| Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). | Q39538478 | ||
| Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells | Q39953544 | ||
| Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells | Q40043213 | ||
| Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. | Q40093675 | ||
| Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant | Q40192741 | ||
| A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer | Q40236523 | ||
| RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer | Q40259898 | ||
| Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes | Q40266897 | ||
| Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. | Q40269139 | ||
| Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state | Q40296469 | ||
| Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. | Q40311505 | ||
| Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death | Q40386567 | ||
| Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity | Q40401113 | ||
| Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. | Q40446699 | ||
| Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer | Q40490715 | ||
| Preferential response of cancer cells to zebularine. | Q40523300 | ||
| Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. | Q40550191 | ||
| Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. | Q40614411 | ||
| Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA | Q40617392 | ||
| Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B | Q40623032 | ||
| The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation | Q40690782 | ||
| DNA damage-induced translocation of the Werner helicase is regulated by acetylation | Q40696914 | ||
| Acetylation of importin-alpha nuclear import factors by CBP/p300. | Q40881413 | ||
| Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells | Q40891228 | ||
| The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote | Q40903819 | ||
| DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine | Q40930861 | ||
| Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification | Q40951949 | ||
| MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. | Q41999930 | ||
| Cellular differentiation, cytidine analogs and DNA methylation | Q42242732 | ||
| MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells | Q42808496 | ||
| How epigenetics integrates nuclear functions. Workshop on epigenetics and chromatin: transcriptional regulation and beyond | Q43205547 | ||
| Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition | Q43561182 | ||
| Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers | Q43578083 | ||
| 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer | Q43590545 | ||
| Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas | Q43670890 | ||
| Hypermethylation leads to silencing of the SYK gene in human breast cancer. | Q43675322 | ||
| Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. | Q43755864 | ||
| Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. | Q43787473 | ||
| CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. | Q43787489 | ||
| Glypican-3 expression is silenced in human breast cancer | Q43796931 | ||
| Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. | Q44259986 | ||
| Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma | Q44302057 | ||
| Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy | Q44435155 | ||
| Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. | Q44615045 | ||
| Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. | Q44653608 | ||
| Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis | Q44800956 | ||
| Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. | Q44816904 | ||
| Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. | Q44836071 | ||
| Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid | Q45191819 | ||
| Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk | Q45238905 | ||
| Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. | Q46689478 | ||
| P433 | issue | 12 | |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 1879-1902 | |
| P577 | publication date | 2008-12-01 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | Epigenomics and breast cancer | |
| P478 | volume | 9 |
| Q92897833 | A novel histone H4 variant H4G regulates rDNA transcription in breast cancer |
| Q35846508 | Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies. |
| Q30872137 | Alcohol and breast cancer: reconciling epidemiological and molecular data |
| Q34181630 | Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. |
| Q39214234 | Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression |
| Q34709370 | Assessment of DNA methylation status in early stages of breast cancer development |
| Q26772961 | Association Between Leptin (-2548G/A) Genes Polymorphism and Breast Cancer Susceptibility: A Meta-Analysis |
| Q64063668 | Association between BRCA1 polymorphisms rs799917 and rs1799966 and breast cancer risk: a meta-analysis |
| Q34235395 | Association between genetic polymorphisms in AURKA (rs2273535 and rs1047972) and breast cancer risk: a meta-analysis involving 37,221 subjects |
| Q36204798 | Biologic characteristics of premalignant breast disease |
| Q27026080 | Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles |
| Q34207688 | Breast cancer genomes--form and function |
| Q40300891 | Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study |
| Q37797702 | Cancer Epigenome |
| Q33920767 | Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. |
| Q34080232 | Chromatin remodeling in mammary gland differentiation and breast tumorigenesis |
| Q51525461 | Correlation between the DNA methylation and gene expression of IGFBP5 in breast cancer. |
| Q37620392 | DNA methylation as a biomarker in breast cancer |
| Q34989097 | DNA methylation epigenotypes in breast cancer molecular subtypes |
| Q54372303 | Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. |
| Q38610743 | Diagnostic and prognostic epigenetic biomarkers in cancer |
| Q57105691 | Epidemiology of Moderate Alcohol Consumption and Breast Cancer: Association or Causation? |
| Q64245254 | Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer |
| Q38946328 | Epigenetic Mechanisms in Psychiatric Diseases and Epigenetic Therapy |
| Q42367979 | Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer |
| Q38296760 | Epigenetic mechanisms of breast cancer: an update of the current knowledge |
| Q36207846 | Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions |
| Q33782392 | Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer |
| Q34556223 | Epigenetic reprogramming of breast cancer cells with oocyte extracts. |
| Q34621606 | Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer |
| Q92917105 | Epigenetics of Breast Cancer: Clinical Status of Epi-drugs and Phytochemicals |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q37662171 | Genetic and epigenetic regulation of AHR gene expression in MCF-7 breast cancer cells: role of the proximal promoter GC-rich region |
| Q39023375 | Genistein inhibits DNA methylation and increases expression of tumor suppressor genes in human breast cancer cells |
| Q46128826 | High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. |
| Q33747365 | High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer |
| Q36517999 | Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest |
| Q55365541 | Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer. |
| Q36152246 | Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer |
| Q26824575 | Linking epithelial-to-mesenchymal-transition and epigenetic modifications |
| Q28269080 | Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology |
| Q36589865 | Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. |
| Q33778433 | Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis |
| Q54484988 | Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. |
| Q92877117 | Methylation of Glutathione-S-Transferase P1 Promotor in Egyptian Females with Breast Cancer |
| Q39003299 | Methylation status of homeobox genes in common human cancers |
| Q39480395 | Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine |
| Q39225627 | Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells |
| Q93186271 | Pathways to Endocrine Therapy Resistance in Breast Cancer |
| Q27011622 | PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2 |
| Q50439916 | Potentiation of growth inhibition and epigenetic modulation by combination of green tea polyphenol and 5-aza-2'-deoxycytidine in human breast cancer cells |
| Q40375288 | Promoter de-methylation of cyclin D2 by sulforaphane in prostate cancer cells |
| Q33702061 | QChIPat: a quantitative method to identify distinct binding patterns for two biological ChIP-seq samples in different experimental conditions |
| Q92316377 | Regulation of Immunity in Breast Cancer |
| Q57178553 | Researches of Epigenetic Epidemiology for Infections and Radiation as Carcinogen |
| Q28066027 | Role of n-3 Polyunsaturated Fatty Acids and Exercise in Breast Cancer Prevention: Identifying Common Targets |
| Q82313928 | Search for new genes involved in breast tumorigenesis by "Omics" analysis |
| Q37522662 | Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients |
| Q35000289 | Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation. |
| Q88221125 | Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents--implications for cancer treatment and chemoprevention |
| Q49544302 | Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer |
| Q36089048 | The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures |
| Q37772356 | The epigenetics of breast cancer |
| Q37696230 | The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells |
| Q45671065 | The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer |
| Q31031642 | Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data |
Search more.